Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

S Vasu; RC Moffett; Janie McCluskey; MH Hamid; Nigel Irwin; Peter Flatt

doi:10.1038/gt.2013.33

Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

S Vasu, RC Moffett, Janie McCluskey, MH Hamid, Nigel Irwin, Peter Flatt

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P

Original language	English
Pages (from-to)	1077-1084
Journal	Gene Therapy
Volume	20
Issue number	11
DOIs	https://doi.org/10.1038/gt.2013.33
Publication status	Published - 1 Nov 2013

Access to Document

10.1038/gt.2013.33

Fingerprint Dive into the research topics of 'Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice'. Together they form a unique fingerprint.

Cite this

@article{9ce37fc11a22419ab60baa5a112f09c5,

title = "Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice",

abstract = "Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P",

author = "S Vasu and RC Moffett and Janie McCluskey and MH Hamid and Nigel Irwin and Peter Flatt",

year = "2013",

month = nov,

day = "1",

doi = "10.1038/gt.2013.33",

language = "English",

volume = "20",

pages = "1077--1084",

journal = "Gene Therapy",

issn = "0969-7128",

publisher = "Springer",

number = "11",

}

TY - JOUR

T1 - Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

AU - Vasu, S

AU - Moffett, RC

AU - McCluskey, Janie

AU - Hamid, MH

AU - Irwin, Nigel

AU - Flatt, Peter

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P

AB - Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P

U2 - 10.1038/gt.2013.33

DO - 10.1038/gt.2013.33

M3 - Article

VL - 20

SP - 1077

EP - 1084

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 11

ER -